A clinical study of pingyangmycin sclerotherapy for venous malformation: an evaluation of 281 consecutive patients. (13th June 2014)

• Record Type: Journal Article
• Authors: Bai, N.; Chen, Y.‐Z.; Fu, Y.‐J.; Wu, P.; Zhang, W.‐N.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 39:Number 5(2014:Oct.)
• Page Start: 521
• Page End: 526
• Publication Date: 2014-06-13
• Subjects: Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12183
• Languages: English
• ISSNs: 0269-4727

Abstract

<abstract abstract-type="main" id="jcpt12183-abs-0001"> <title>Summary</title> <sec id="jcpt12183-sec-0001" sec-type="section"> <title>What is known and objective</title> <p>In China, lidocaine together with 2 mg/mL of pingyangmycin (PYM, also known as bleomycin A5) is recommended for the treatment of venous malformations (VMs). The purpose of this study was to investigate whether lidocaine has a synergistic effect with PYM in improving the therapeutic outcomes of patients with VMs. Additionally, this study aimed to evaluate the outcomes of sclerotherapy for VMs using an intralesional injection of a low concentration of PYM (0·5 mg/mL).</p> </sec> <sec id="jcpt12183-sec-0002" sec-type="section"> <title>Methods</title> <p>A total of 281 patients with VMs were treated with 0·5 or 2 mg/mL of PYM with or without lidocaine and dexamethasone (DEX). All of the patients received a direct intralesional injection at a rate of 1 mL/min, and the volume of the solution varied from 1·5 to 6·0 mL per injection.</p> </sec> <sec id="jcpt12183-sec-0003" sec-type="section"> <title>Results and discussion</title> <p>No significant differences were observed in the clinical outcomes between the PYM and PYM + lidocaine treatment groups (<italic>P </italic>><italic> </italic>0·05). The clinical outcomes were similar between the groups that were treated with 0·5 and 2 mg/mL of PYM, but the swelling and pain in the patients who were treated with 0·5 mg/mL of PYM were less severe compared with the patients who were treated with 2 mg/mL of PYM. A total of 29 patients with VM lesions on the glans penis were treated with 0·5 mg/mL of PYM + 0·5% lidocaine. Of these patients, 26 were cured, whereas three experienced a marked improvement.</p> </sec> <sec id="jcpt12183-sec-0004" sec-type="section"> <title>What is new and conclusion</title> <p>Lidocaine does not have a synergistic effect with PYM in improving the therapeutic outcomes of patients with VMs. Sclerotherapy with a low concentration of PYM (0·5 mg/mL) combined with lidocaine and DEX is a safe and effective therapy for small superficial VMs of critical organs, such as the lips and the glans penis.</p> </sec> </abstract>